Table 2 Treatment, follow-up, complications and sequelae.

IV antibiotics

Cephalosporins–no. (%)

Linezolid–no. (%)

Glycopeptides–no. (%)

Aminoglycosides–no. (%)

Meropenem–no. (%)

Amoxicillin-clavulanate–no. (%)

Rifampicin–no. (%)

Quinolones–no. (%)

Fosfomycin–no. (%)

219 (68.7)

112 (35.1)

103 (32.3)

77 (24.1)

35 (11.0)

33 (10.3)

25 (7.8)

20 (6.3)

13 (4.1)

OS antibiotics

Quinolones–no. (%)

Linezolid–no. (%)

Amoxicillin-clavulanate–no. (%)

Cephalosporins–no. (%)

Rifampicin–no. (%)

Clindamycin–no. (%)

IREP–no. (%)

Glycopeptides–no. (%)

123 (38.6)

79 (24.8)

75 (23.5)

43 (13.5)

17 (5.3)

7 (2.2)

7 (2.2)

6 (1.9)

IV therapy (days)–median (range)

 < 14 days–no. (%)

 > 14 days–no. (%)

OS therapy (days)–median (range)

 < 14 days–no. (%)

 > 14 days–no. (%)

Total antibiotic therapy (days)–median (range)

 < 6 weeks–no. (%)

 > 6 weeks–no. (%)

21 (14–29)

58 (18.2)

261 (81.8)

16 (12–24.5)

92 (28.8)

227 (71.2)

42 (31–49)

305 (95.6)

12 (3.8)

Local complications

Soft-tissue abscess–no. (%)

Perilesional cellulitis–no. (%)

Myositis–no. (%)

Bone sequestration–no. (%)

139 (43.6)

118 (37)

67 (21.0)

40 (12.5)

Surgical intervention

Curettage–no. (%)

Arthrocentesis–no. (%)

Osteosynthesis–no. (%)

40 (12.5)

11 (3.4)

12 (3.8)

Hospitalization (days)–median (Q1-Q3)

22.5 (16–31)

Follow-up–median; Q1–Q3 (range)

8; 4–14 (0–60)

Relapse–no. (%)

17 (5.3)

Sequelae–no. (%)

43 (13.5)

Chronic osteomyelitis–no. (%)

45 (14.1)